Because you’re never done being healthy, here’s an annual membership with 10+ EXCLUSIVE reports & features delivered to you throughout the year to keep fueling your health journey.10+ reports and features will be added annually January to December.
- Includes everything from our Health + Ancestry kit
- PLUS access to exclusive reports that help you learn about your heart health, how you process certain medications, migraine, and more
- Enhanced ancestry features
There is a lot to consider with genetic testing. We encourage you to review relevant information about Pharmacogenetics**Learn about Considerations and Limitations for Pharmacogenetics Reports Carrier Status*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health Risks and Genetic Health Risk*Learn about Considerations and Limitations for Health Predispositions Reports, Carrier Status Reports and Genetic Health Risks reports.
23andMe+ members get
even more insights into their health.
Get our base Health + Ancestry Service with 150+ personalized DNA reportsLearn more about Health + Ancestry
10+Premium reports and features throughout the year
Take a look at what you'll get from the start
Heart Health.Exclusive DNA insights to stay proactive with your heart health.
Get a better picture of what may be in store for your heart’s health and learn about lifestyle factors and steps that can help you stay healthy.
.Get smarter about the prescriptions you’re taking.
Medications don’t always “work” the same way in different bodies. Discover how your DNA may impact the way your body processes certain medications with three Pharmacogenetics reports plus Medication Insights on citalopram and clopidogrel. Share these reports with your doctor to make smarter decisions together.
Plus more exclusive DNA insights to better understand your health.
Advanced Ancestry Features.Research your ancestry faster and more efficiently.
Advanced DNA Relative filters
Quickly sort through your relatives to find the one who helps complete your DNA story.
Check out the latest 23andMe+
Our scientists are always working on new ways for you to benefit from your DNA, so you’ll get personalized premium reports delivered to you throughout the year to help you optimize your health plan.‡
Stay in the know.
Keep up-to-date with new discoveries and exclusive promotions on our DNA test kits.
*23andMe health predisposition reports include both reports that meet FDA requirements for genetic health risks and reports which are based on 23andMe research and have not been reviewed by the FDA. The test uses qualitative genotyping to detect select clinically relevant variants in the genomic DNA of adults from saliva for the purpose of reporting and interpreting genetic health risks. It is not intended to diagnose any disease. Your ethnicity may affect the relevance of each report and how your genetic health risk results are interpreted. Each genetic health risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. The test is not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication, how much of a medication you should take, or determine any treatment. Our carrier status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future, the health of your fetus, or your newborn child's risk of developing a particular disease later in life. For certain conditions, we provide a single report that includes information on both carrier status and genetic health risk. Warnings & Limitations: The 23andMe PGS Genetic Health Risk Report for BRCA1/BRCA2 (Selected Variants) is indicated for reporting of the 185delAG and 5382insC variants in the BRCA1 gene and the 6174delT variant in the BRCA2 gene. The report describes if a woman is at increased risk of developing breast and ovarian cancer, and if a man is at increased risk of developing breast cancer or may be at increased risk of developing prostate cancer. The three variants included in this report are most common in people of Ashkenazi Jewish descent and do not represent the majority of BRCA1/BRCA2 variants in the general population. This report does not include variants in other genes linked to hereditary cancers and the absence of variants included in this report does not rule out the presence of other genetic variants that may impact cancer risk. The PGS test is not a substitute for visits to a healthcare professional for recommended screenings or appropriate follow-up. Results should be confirmed in a clinical setting before taking any medical action. For important information and limitations regarding each genetic health risk and carrier status report, visit 23andme.com/test-info/
**23andMe PGS Pharmacogenetics reports: The 23andMe test uses qualitative genotyping to detect 3 variants in the CYP2C19 gene, 2 variants in the DPYD gene and 1 variant in the SLCO1B1 gene in the genomic DNA of adults from saliva for the purpose of reporting and interpreting information about the processing of certain therapeutics to inform discussions with a healthcare professional. It does not describe if a person will or will not respond to a particular therapeutic and does not describe the association between detected variants and any specific therapeutic. Our CYP2C19 Pharmacogenetics report provides certain information about variants associated with metabolism of some therapeutics and provides interpretive drug information regarding the potential effect of citalopram and clopidogrel therapy. Results for SLCO1B1 and DPYD and certain CYP2C19 results should be confirmed by an independent genetic test prescribed by your own healthcare provider before taking any medical action. Warning: Test information should not be used to start, stop, or change any course of treatment and does not test for all possible variants that may affect metabolism or protein function. The PGS test is not a substitute for visits to a healthcare professional. Making changes to your current regimen can lead to harmful side effects or reduced intended benefits of your medication, therefore consult with your healthcare professional before taking any medical action. For important information and limitations regarding Pharmacogenetics reports, visit 23andme.com/test-info/pharmacogenetics/